Victorian Melanoma Service Research

The Victorian Melanoma Service (VMS) is one of Australia’s largest multidisciplinary treatment services for melanoma. Our team of expert doctors, researchers, nurses and staff are focused on research and treatment innovations that are instrumental in changing the future of melanoma treatment. 

Melanoma research is also conducted by Medical Oncology, in partnership with the Victorian Melanoma Service and the Melbourne Melanoma Project.

Find out more about Medical Oncology melanoma research.

Achievements

  • Professor Catriona McLean, Head of Anatomical Pathology
    Jan 2019 - Officer (AO) in the General Division of The Order of Australia
    For distinguished service to medicine in the field of academic and clinical neuropathology, and as a role model and mentor. 

  • Profesor Kelly - After founding the Victorian Melanoma Service in 1994, dermatologist Prof Kelly went on to lead the service until 2018.
    Jan 2018 - Member of Order of Australia
    Prof. Kelly received the award for significant service to medicine through the management and treatment of melanoma, as a clinician and administrator, and to education. 

  • Dr Victoria Mar received an Award for Thesis Excellence from the Monash School of Public Health and Preventive Medicine for her doctoral thesis ‘Clinical and molecular analyses of aggressive melanoma.'
  • Dr Charles Xie was awarded the 2015 Monash Comprehensive Cancer Consortium Prize for Best Poster in Cancer Research at Alfred Health Week for his poster entitled ‘Scalp melanoma - distinctive high risk clinical and histological features’. Dr Xie also a won Best Poster prize at the 2015 Australasian College of Dermatologists Annual Scientific Meeting.
  • Dr Diana Norris and Dr Charles Xie received World Congress of Dermatology Trainee Scholarships to attend the 23rd World Congress of Dermatology in Vancouver, Canada in 2015. 

Publications

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial

Ackermann DM, Smit AK, Janda M, van Kemenade CH, Dieng M, Morton RL, Turner RM, Cust AE, Irwig L, Hersch JK, Guitera P, Soyer HP, Mar V, Saw RPM, Low D, Low C, Drabarek D, Espinoza D, Emery J, Murchie P, Thompson JF, Scolyer RA, Azzi A, Lilleyman A, Bell KJL

(2021), Trials, 22(1), 324

DOI: 10.1186/s13063-021-05231-7

The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World

Felmingham CM, Adler NR, Ge Z, Morton RL, Janda M, Mar VJ

(2021), Am J Clin Dermatol, 22(2), 233-42

DOI: 10.1007/s40257-020-00574-4

Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals

Bakshi A, Yan M, Riaz M, Polekhina G, Orchard SG, Tiller J, Wolfe R, Joshi A, Cao Y, McInerney-Leo AM, Yanes T, Janda M, Soyer HP, Cust AE, Law MH, Gibbs P, McLean C, Chan AT, McNeil JJ, Mar VJ, Lacaze P

(2021), JNCI-J NATL CANCER I, 113(10), 1379-85

DOI: 10.1093/jnci/djab076

View all publications for Victorian Melanoma Service Research
News & articles
from Alfred Health
Read latest news